Usa Britain Canada covid-19 pandemic vaccine infection Usa Britain Canada

GSK plans to produce one billion pandemic vaccine adjuvant doses

Reading now: 405
www.pharmaceutical-technology.com

GSK intends to manufacture, fill and finish adjuvant for Covid-19 vaccines at sites in the UK, US, Canada and Europe. Credit: GSK.

GlaxoSmithKline (GSK) is set to produce one billion doses of its pandemic vaccine adjuvant system next year to support adjuvanted Covid-19 vaccine candidates development.

The news comes after the company performed global manufacturing review and decided to invest for expanded manufacturing capacity.

In the last flu pandemic, GSK pandemic adjuvant decreased the amount of vaccine protein needed per dose, facilitating the production of more vaccine doses.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA